Advanced kidney carcinoma: decision paths and therapeutic perspectives

Valentina Da Prat, Isabella Testa, Giuseppe Procopio



Treatment of kidney cancer represents an open challenge for scientists and clinicians. In fact,renal tumours are resistant to virtually all of the currently available chemotherapeutics, beingonly partially sensitive to immunological agents. During the last decade, knowledge of geneticbasis of cancer has grown considerably. This has lead to an authentic revolution in the clinicalmanagement of renal tumours: the introduction of targeted therapies. Novel agents addressangiogenic signalling pathways through inhibition of the vascular endothelial growth factor(VEGF) or the mammalian target of rapamycin (mTOR). However, there is still no greatevidence favouring one drug over the others. This underlines the need for decision-making toolsin renal cell cancer treatment, in order to rationalise the choice of appropriate targeted agentsand to enable individualised clinical management. This is a brief overview on the state of theart of the treatment of metastatic renal tumour.


Renal carcinoma; Oncology; Antiangiogenic therapy; Tyrosin kinase inhibitors

Full Text



  • Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-17;
  • Mattei J, da Silva RD, Sehrt D, et al. Targeted therapy in metastatic renal carcinoma. Cancer Lett 2014; 343: 156-60;
  • Fojo AT, Shen DW, Mickley LA, et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-7
  • AIOM/AIRTUM. I numeri del cancro in Italia. 2013. Disponibile all’indirizzo (ultimo accesso settembre 2014)
  • Kim SP, Murad MH, Thompson RH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012; 188: 51-7;
  • Tan H-J, Norton EC, Ye Z, et al. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012; 307: 1629-35;
  • Abara E, Chivulescu I, Clerk N, et al. Recurrent renal cell cancer: 10 years or more after nephrectomy. Can Urol Assoc J 2010; 4: E45-E49
  • Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am 2008; 35: 581-92;
  • Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
  • Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-5;
  • Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009; 104: 1585-9;
  • Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11;
  • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24;
  • Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8;
  • Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res 2010; 16: 5923-7;
  • Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12;
  • Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67: 1257-64;
  • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34;
  • Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 2013; 108: 311-8;
  • Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-9;
  • Verzoni E, Grassi P, Testa I, et al. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med 2014; 7: 107-16
  • Motzer BRJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell. J Clin Oncol 2002; 20: 289-96;
  • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81;
  • Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56;
  • Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-90;
  • Albiges L, Molinie V, Escudier B. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? Oncologist 2012; 17: 1051-62;
  • Kroeger N, Xie W, Lee J-L, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119: 2999-3006;
  • Patard J-J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23: 2763-71;
  • Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9;
  • Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. European Association of Urology, 2014. Disponibile all’indirizzo (ultimo accesso settembre 2014)
  • Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117: 501-9;
  • Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22: 295-300;
  • Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369: 722-31;
  • Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32: 1412-8;
  • Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-32;
  • McDermott DF. The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Med Oncol 2009; 26 (Suppl 1): 13-7;
  • Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-9;
  • Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63;


Abstract: 536 views
HTML: 1538 views
PDF: 959 views


  • There are currently no refbacks.

© SEEd srl